/ /

  • linkedin
  • Increase Font
  • Sharebar

    B + L dedicated to eye care with strong portfolio, new programs

     

    Strong portfolio

    The company already has a strong portfolio in cataract and retinal surgery, a portfolio that was strengthened with the acquisition of Synergetics at the end of 2015. In ophthalmic pharmaceuticals, the focus is on research and development. The company is pursuing a mixed strategy that combines internal research programs as well as business development, outside acquisitions, and expanding life-cycle opportunities across existing products.

    “We have a very integrated solution for glaucoma,” Valorie said. “We recognize that there is no one-stop shop for glaucoma because all patients are not going to need the same solution. There is a need for a mix of solutions, which is why we are working on a surround-sound portfolio that leverages pharmaceutical, surgical, and diagnostic options to help you treat glaucoma patients going forward.”

    Recent: Glaucoma surveillance essential for optimizing patient outcomes

    One of the newest additions to the B + L glaucoma portfolio may be latanoprostene bunod (LBN), the first prostaglandin analogue + nitric oxide donating moiety to be submitted for FDA marketing approval.

    LBN metabolizes into latanoprost-free acid and nitric oxide with two distinct mechanisms of action. Latanoprost-free acid increases uveoscleral outflow to reduce IOP. At the same time, nitric oxide leads to a relaxation of the trabecular meshwork to increase outflow and further decrease IOP.

    The company is looking forward to a response from FDA during the first half of 2016 and a product launch during the second half of the year. If approved, LBN would be the first nitric oxide donating ophthalmologic product on the market.

    More: Three companies on the “Horizon” with glaucoma drugs

    “B + L continues to build on our long heritage of serving eye customers and patients with eye disease,” Ms. Valorie said. “We are committed over the long term to glaucoma. The LBN project lets us take that first step. It is an opportunity we can build on and we have the firm commitment from our parent company Valeant to do so. We continue to work towards improving options across the eye care space. We have a very deep bench of dedicated people and glaucoma is in the forefront of our vision of the future.”

    Subscribe Here For Free eNewsletter

     

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results